Kerendia (Finerenone)

Finerenone is a selective, non‑steroidal antagonist of the mineralocorticoid receptor. By blocking this receptor, it prevents aldosterone‑driven inflammation and fibrosis in the kidneys, thereby preserving renal structure and function in patients with diabetic kidney disease.

The prescribed dose of Kerendia is determined by the treating physician based on the patient’s kidney function, serum potassium, and overall clinical status. Typical starting strengths are 10 mg once daily, with possible adjustment to 20 mg as clinically indicated.

Safety of Finerenone in pregnancy and lactation has not been established. It should be avoided during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended without a thorough risk‑benefit assessment by the healthcare provider.

To order Kerendia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kerendia (finerenone) is a non‑steroidal antagonist, offering greater selectivity for the mineralocorticoid receptor than steroidal agents such as spironolactone or eplerenone. This selectivity may translate into a lower incidence of hormonal side effects while maintaining efficacy in reducing renal inflammation and fibrosis.

Kerendia tablets should be stored below 25 °C in their original container, protected from moisture and direct sunlight. Do not store in a refrigerator or freezer. Keep out of reach of children and dispose of any unused product according to local regulations.

Kerendia is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, acute kidney injury, and marked hypotension. Patients should be monitored regularly for serum potassium and renal function, and any signs of these complications should prompt immediate medical evaluation.

Kerendia should not be used in patients with known hypersensitivity to finerenone, those with severe hyperkalemia (serum potassium >5.5 mmol/L), end‑stage renal disease requiring dialysis, or in pregnant women unless the potential benefit outweighs the risk. Caution is also advised for patients with significant hepatic impairment.